title: Efficacy of LAI in first episode psychosis: an observational study--clinical reports.
abstract: The use of antipsychotics, especially second generation antipsychotics, represents the milestone treatment of "first episode of psychosis" (FEP). Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, as it is well acknowledged that "duration of untreated psychosis" (DUP) is one of the main factor that negatively affects prognosis: a longer DUP is highly correlated to reduced response to treatment, poor clinical and social outcomes, and an overall worst prognosis. Long-acting injectable (LAI) formulations of antipsychotics have traditionally been used for those patients with psychosis with the most severe symptoms, poorest compliance, most hospitalizations and poorest outcomes; moreover it seems that psychiatrists tend to prescribe LAI at the latter stages of the disease. We retrospectively collected clinical and sociodemographic data regarding patients consecutively presenting with symptoms of FEP attending the Community Mental Health Service (CMHS) in Foggia from 1st June 2014 to 31st May 2015. We selected patients who attended the CMHS in Foggia with symptoms of FEP. Different scales were administered to assess symptoms severity, quality of life, side effects, adherence, and overall functionality. In our sample LAI treatment was found to be effective in treating symptoms associated to FEP, improved quality of life and it was associated with a clinically irrelevant incidence of extrapyramidal side effect. Considering that achieving a full symptoms remission in people affected by FEP is associated to better outcomes, and that DUP is associated to poor prognosis, LAIs could play an important role in improving overall recovery.
authors.affiliation: Community Mental Health Service, Department of Mental Health, AUSL Foggia, Foggia, Italy, alba.cervone@gmail.com.
authors.forename: Alba
authors.initials: A
authors.lastname: Cervone
authors.forename: Antonio
authors.initials: A
authors.lastname: D'Onghia
authors.forename: Maria
authors.initials: M
authors.lastname: Ferrara
authors.forename: Claudio R M
authors.initials: CR
authors.lastname: Massaro
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations